Skip to main content
. Author manuscript; available in PMC: 2022 Mar 28.
Published in final edited form as: Oncogene. 2020 Dec 15;40(5):1012–1026. doi: 10.1038/s41388-020-01565-9

Figure 1: RGN expression correlates with late recurrence in patients.

Figure 1:

(A) Outline of differentially expressed genes analysis between Early recurrence and Late recurrence group. (B–C) Patients in TCGA were stratified based on their expression levels of RGN and overall- (B) and recurrence-free- survival (C) were examined. (D–E) Patients in GSE21034 (D) and GSE6919 (E) were stratified based on their RGN expression and its association with recurrence-free survival was examined. The overall- and recurrence-free survival plots in figure B–E were analyzed by log-rank (Mantel-cox) test. (F) Expression of indicated genes were examined in patients with No-relapse (n=541) and Relapse disease (n=11) using the TCGA dataset. Data were analyzed using unpaired t-test. (G) RGN expression was examined in patient normal, primary and metastatic primary tumors using the GSE21034 dataset. One way anova was performed to analyze the data (H) Immunohistochemistry staining was performed for patient tumor specimens to examine RGN expression. *, P-value<0.05, ** P-value<0.01 and ***, P-value<0.0001.